Imeglimin. A new and novel drug thats better than Metformin

cl-user · January 12, 2026, 4:01pm

Ordered some from India.

For me it’s more a replacement for Plioglitazone which works well but has some safety issues.
Also my DEXA fat % went from 14% to 16% with Plioglitazone.

Metformin did not do anything at all for me.

I did a Gemini Pro deep research: Bioenergetic Pharmacotherapy in Type 2 Diabetes: A Comprehensive Analysis of Imeglimin Interactions, Comparative Safety, and Physiological Adaptations

That includes interaction with rapamycin, empagliflozin, exercise, etc.

Table 1: Comparative Safety and Efficacy Profile: Imeglimin vs. Pioglitazone

Feature	Pioglitazone (TZD)	Imeglimin (Glimin)	Clinical Consequence
Primary Target	Nuclear PPARγ Receptor	Mitochondrial Complex I/III	Imeglimin avoids nuclear transcription side effects.
Heart Failure Risk	Increased (Boxed Warning)	Neutral (Potential Benefit)	Imeglimin is safer for patients with cardiac history.
Edema	Frequent (Renal Na+ reabsorption)	Rare / Absent	Imeglimin preferred in patients prone to volume overload.
Bone Fracture Risk	Increased (Marrow adipogenesis)	Neutral	Imeglimin preferred in postmenopausal women/elderly.
Weight Effect	Weight Gain (Adipogenesis + Fluid)	Neutral	Imeglimin avoids exacerbating obesity.
Liver Fat	Reduces (Potent)	Reduces (Moderate)	Both benefit MASH, but Pioglitazone has more data.
Onset of Action	Slow (Weeks/Months)	Rapid	Imeglimin offers faster glycemic control.

Table 2: Mechanism of Interaction: Imeglimin + Empagliflozin

Component	Empagliflozin Contribution	Imeglimin Contribution	Synergistic Outcome
Glycemia	Urinary glucose excretion (Insulin Independent)	Insulin sensitization + GSIS (Insulin Dependent)	Potent HbA1c reduction covering all mechanisms.
Cardiac	Hemodynamic unloading + Ketone fuel	Mitochondrial efficiency + Endothelial function	Structural and metabolic cardiac remodeling.
Renal	Reduced glomerular pressure	Reduced oxidative stress	Preservation of nephron mass.
Liver	Reduced hepatic fat	Reduced lipogenesis + fibrosis	Mitigation of MASH progression.

Table 3: Summary of Imeglimin Interactions and Effects

Domain	Interaction / Comparison	Key Outcome / Mechanism
Pharmacology	vs. Metformin	Competitive vs. Non-competitive Complex I inhibition; Imeglimin rescues Complex III and amplifies GSIS.
Safety	vs. Pioglitazone	Imeglimin has NO heart failure, edema, or bone fracture risk. Weight neutral.
Synergy	w/ Tirzepatide	Complementary beta-cell effects: Tirzepatide stimulates, Imeglimin protects (mitochondrial buffering).
Synergy	w/ Empagliflozin	Full Cardio-Renal protection: SGLT2i (hemodynamic) + Imeglimin (metabolic/endothelial).
Longevity	w/ Rapamycin	Imeglimin (AMPK/SIRT1) rescues mitochondrial biogenesis inhibited by Rapamycin (mTORC1 blockade).
Muscle	Strength Training	Increases strength (~13%) without hypertrophy. Improves NMJ/Bioenergetics.
Muscle	Endurance	Enhances PGC-1α and mtDNA. Potentially additive to exercise adaptations.
Renal	TWINKLE Study	Safe in eGFR < 45 mL/min (unlike Metformin). No lactic acidosis signal.

JuanDaw · January 12, 2026, 7:29pm

Also cited in the post of Dr. Fraser (citation #7)

In the present study, only imeglimin enhanced insulin secretion and the effect on insulin sensitivity was similar between imeglimin and metformin; however, the reduction of HbA1c in both drugs was similar at 24 weeks. This may be explained by that metformin has the glucose‐lowering effect via mechanisms not involving insulin signal such as enhancing release of glucose into the intraluminal space of the intestine or influencing the gut microbiota.

Is that a desired result? Isn’t increased insulin age accelerating?

In humans, epidemiological studies suggest a pro-aging effect of insulin. Insulin resistance increases with aging, but centenarians usually preserve normal glucose tolerance, low levels of fasting insulin and higher insulin sensitivity, when compared with adults > 75 years of age (52–54). The higher longevity in shorter men is also associated with lower fasting insulin concentrations (55).

Denet · January 14, 2026, 1:01am

again using AI to help: Imeglimin (brand name Twymeeg) is a first-in-class oral antidiabetic approved in Japan since 2021 for Type 2 diabetes. It shares some mechanisms with metformin but works differently at the mitochondrial level, which is why longevity enthusiasts are interested in it.

How It Differs from Metformin

Feature	Metformin	Imeglimin
Complex I	Non-competitive inhibition (blunts respiration)	Competitive modulation (preserves oxidative capacity)
Complex III	No effect	Corrects dysfunction, reduces ROS
NAD+ effect	Indirect	Direct upregulation via NAMPT
Insulin secretion	None (works via liver)	Amplifies glucose-stimulated insulin secretion (GSIS)
GI tolerance	Often poor (diarrhea)	Generally better tolerated
Lactic acidosis risk	Rare but possible	Lower theoretical risk
HbA1c reduction	~1.0–1.2% at full dose	~0.6–0.9% (head-to-head similar to lower-dose metformin)
Cost	Very low (generic)	High (patented)

Longevity Angle

The appeal for healthspan is its “mitochondrial optimizer” profile—it reduces ROS via reverse electron transport while preserving ATP production, and it boosts the NAD+ salvage pathway through NAMPT induction. However, no human clinical data currently support lifespan extension, and no large cardiovascular outcome trials (CVOTs) exist yet.

Exercise and Muscle

Unlike metformin, which can blunt muscle hypertrophy (per the MASTERS trial), emerging data suggest imeglimin may enhance muscle strength (~13% improvement in one cohort) without blocking exercise adaptations. It activates Akt signaling (which supports mTORC1/growth) rather than purely braking it through AMPK, and it enhances PGC-1α for mitochondrial biogenesis.

Practical Notes

Dose: 1,000 mg twice daily (Japan-approved); dose reductions for CKD are off-label but used clinically.
Availability: Not approved in the US/EU, but available from Indian generics (e.g., Zydus) at reasonable cost.
Rapamycin interaction: Mechanistically, imeglimin’s AMPK/SIRT1 activation may actually rescue mitochondrial biogenesis that rapamycin’s mTORC1 blockade inhibits—potentially complementary rather than counteractive.

Bottom Line

Imeglimin is a promising “super-metformin” candidate for those who cannot tolerate metformin or want more targeted mitochondrial support, especially if they exercise regularly. The glycemic efficacy is slightly weaker than full-dose metformin, but the safety profile (no lactic acidosis signal, better GI tolerance, neutral on weight/heart failure/bone) and potential exercise compatibility make it attractive. That said, it remains speculative for longevity until human outcome trials are completed

CronosTempi · January 15, 2026, 4:13am

Certainly a valid concern. However, it is super important to try to understand the MOA (mechanism of action) of any drug before making a decision about taking it. There are drugs that increase insulin output, such as sulfonylureas, meglitinides, glp-1ra etc. However, you have to ask about the MOA of any particular class of drugs. If the drugs force greater insulin output from beta cells leading to beta cell exhaution, that can be a long term negative. But what if your pancreas would release a “normal” amount of insulin in response to glucose levels, but it’s prevented by some kind of defect in some beta cell pathway, either production or release or whatever. Then, removing that defect simply restores insulin levels to “normal” - in that scenario increased insulin levels are not a negative.

That’s why it is so crucial to try to establish the MOA. But let us assume that imeglimin increases insulin production through repairing a defect along the beta cell pathway.

Imeglimin Amplifies Glucose-Stimulated Insulin Release from Diabetic Islets via a Distinct Mechanism of Action

https://www.biorxiv.org/content/10.1101/2020.10.20.346841v1

Does that mean you should add imeglimin to your drug stack if you have elevated A1c? Not necessarily. Let us go back to a fundamental concept, frequently invoked by Ralph DeFronzo, that diabetes (and prediabetes is just along the spectrum of poor glucose control) is a multifactorial disease with many causes, as in the defect may be along any pathway of glucose control. If it so happens, that your poor glucose control is down to a specific defect in the beta cell pathway that imeglimin addresses, you are golden: go take this drug. But that may not be the case at all. For example, many prediabetics, or even people who are normoglycemic have very high insulin levels. Clearly their problem is not an inadequate production or release of insulin by the pancreas. In that scenario, trying to fix a non-existant defect in the pancreas with imeglimin as a way to normalize glucose metabolism might not yield the desired results. Addressing any disease starts with the correct diagnosis. You must establish - and the more precisely the better - where does the defect in glucose metabolism lie in your case. And once you’ve established that, you can try to address it with the appropriate drug.

Unfortunately, we face two problems. Problem one, is that we often are not sure where the problem lies, and problem two is that a given drug may have MOA that is not transparent to us, or has multiple pathways (a “dirty” drug, like metformin). Sure, you can say metformin/sglt2i/pio/glp-1ra “brings down A1c” - but if that’s all the study shows, you really can’t be sure that it will work for you or indeed that it is appropriate and not counterproductive.

Just as an example, I take myself. My A1c is consistently high (5.7-5.9). My morning fasting blood glucose is also high (~110mg/dL). However, my insulin levels are also high. It doesn’t seem like the problem for me is inadequate insulin release. For the amount of insulin I pump out, my glucose levels ought to be lower (HOMA-IR 1.7 in my case) as reflected by A1c. I therefore am going to hold off on imeglimin for the time being. It seems to me, the problem here is somewhere else - either insulin sensitivity or excessive hepatic neoglucogenesis. That would make pioglitazone more interesting to me (in my case). But the complication is of course that imeglimin also works along multiple pathways muddying the issue - is it worth hammering the pancreas with an unnecessary “fix” because the drug also suppresses hepatic neoglucogenesis? Maybe. Or maybe I’d prefer a more targeted intervention, a drug that addresses my defect and not anything else (maybe a luxury I don’t have!).

My point here is this: we often read that a given drug does something (lowers glucose, A1c, lipids, homocysteine whatnot) and we decide to spring for it, especially if we suffer from some issue (excessive glucose levels, lipid levels whatnot). But that may transpire to be a very unwise choice.

Instead you need to ask: given my problem (say, glucose control) - will drug X (say, imeglimin) help in my case? Unless you know, why take the drug? What is the MOA of that drug and what is your defect and etiology of your pathology, does that drug address it, or does it merely give you side effects without benefits or merely surface benefits which are disastrous longer term (insulin therapy for some T2DM cases). Perhaps imeglimin might work short term - but will it work for you long term, or be counterproductive?

And that’s why I’m interested in the MOA of this drug. And why it takes me a long time to research a drug before I even consider taking it. YMMV.

entechad · January 16, 2026, 6:55am

Is there a trusted pharmacy that is typically used?

RapAdmin · January 16, 2026, 7:00am

See here:

Buy Rapamycin Online - List of Reliable Pharmacies
What Brands of Medications to buy: Generally Good Indian Pharma Companies

CronosTempi · January 16, 2026, 7:51am

Doing further research, I am wondering about drug interactions. For example, what if your version of poor glucose control does not result from any defect in beta cells GSIS, and since one way in which imeglimin works is that it “fixes” GSIS, you may surmise that imeglimin might not be for you. But what if you are also taking another drug, say, sirolimus, which longer term or with some protocols (daily dosing?) actually damages beta-cells GSIS? Now you might be adding this defect to your glucose control issues, and what if under those circumstances (i.e. you taking sirolimus) taking imeglimin might make sense, whereas without sirolimus it does not.

Evidence for Rapamycin Toxicity in Pancreatic β-Cells and a Review of the Underlying Molecular Mechanisms

https://diabetesjournals.org/diabetes/article/62/8/2674/34093/Evidence-for-Rapamycin-Toxicity-in-Pancreatic

Quote:

“Overall, the majority of these studies demonstrate significant effects of rapamycin on glucose homeostasis, and the combined evidence strongly suggests that rapamycin adversely affects GSIS from β-cells.”

Of course, GSIS from beta-cells can be impacted through various mechanisms, so it remains to be shown whether imeglimin can “fix” the damage sirolimus does to beta-cells. Again we need to take a closer look at the MOA of both drugs to guess at any possible interaction, and then test it. The research continues.

desertshores · January 16, 2026, 4:08pm

“suppresses hepatic neoglucogenesis” “fixes GSIS”

Aren’t these good things? GSIS declines with age.

(Gemini)

"Yes, Imeglimin suppresses hepatic gluconeogenesis (the production of new glucose by the liver). It is a core part of its “dual-benefit” mechanism of action, which targets the liver, skeletal muscle, and pancreatic beta cells.

Mechanism in the Liver

Imeglimin reduces excessive glucose production through several mitochondrial-dependent pathways:

Mitochondrial Rebalancing: It acts on the mitochondrial respiratory chain by partially and competitively inhibiting Complex I and restoring the activity of Complex III.

Energy Regulation: This rebalancing lowers the ATP/ADP ratio and increases mitochondrial redox potential in hepatocytes, which reduces the driving force for gluconeogenesis."

Ref

"Age-Related Decline in GSIS

In humans, beta cell function generally declines with age, estimated at a rate of approximately 1% per year. This decline is often independent of peripheral insulin resistance or body mass index.

Reduced Stimulated Secretion: Islets from younger donors (<40 years) typically exhibit significantly higher GSIS than those from older donors.

Elevated Basal Secretion: Aging is often associated with an increase in basal (fasting) insulin secretion, which may represent a compensatory state but also reduces the cell’s “dynamic range” when stimulated by high glucose.

Mechanisms of Dysfunction."

Ref1

CronosTempi · January 20, 2026, 7:38am

Apparently in a percentage of users SGLT2i can increase the risk of erythrocytosis (see paper below). If imeglimin prolongs how long erythrocytes persist in the serum, then wouldn’t the concurrent use of both drugs further elevate the risk of erythrocytosis?

From the canagliflozin thread, a paper posted by @Davin8r:

Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes

Davin8r · January 20, 2026, 3:11pm

It certainly could, and would be potentially even worse with testosterone + SGLT2i + imeglemin. T and SGLT2i mainly work by stimulating production of RBC, so if then you add in a drug that reduces RBC senescence/removal then I’d expect to see even more of an increase in hemoglobin/hematocrit.

egorvj · January 24, 2026, 9:24pm

Then slow titration should be used, with frequent blood draws. And looking for hemo increasing.

cl-user · January 24, 2026, 9:27pm

Got it. Starting today. BTW I already stopped Plioglitazone 3 weeks ago.
I will report back here.

egorvj · January 24, 2026, 9:31pm

Have you made any tests? Glucose maybe?

cl-user · January 24, 2026, 9:40pm

I’m starting today. I use a CGM and I take fingerpick glucose every morning.

CronosTempi · January 24, 2026, 9:58pm

Fantastic. Super interested in this. Please keep us posted. Also very interested in BG now that you’ve stopped pio, but before you start up on ime otherwise it’ll be hard to disentangle the effects of one vs the other. I think ime is less potent in glucose lowering than metformin, and since met did nothing much for you (did zilch for me), I think if there’s an effect, it’ll really be down to the different MOA.

egorvj · January 24, 2026, 10:02pm

Well, your reports with numbers will be much appreciated.

cl-user · January 24, 2026, 10:11pm

Same for me. metformin did not change anything. That said imeglimin has more MOAs than metformin:

(Gemini 3 pro)

Imeglimin does everything Metformin does (sensitizes the body to insulin), but it also stimulates the pancreas to release insulin in response to glucose (Glucose-Stimulated Insulin Secretion, or GSIS).

Imeglimin promotes the synthesis of NAD+ (via the salvage pathway). Increased NAD+ leads to higher intracellular calcium levels in pancreatic beta-cells, which is the direct trigger for insulin release.

Imeglimin has been shown to prevent the opening of the Mitochondrial Permeability Transition Pore (mPTP) . When this pore opens, cells die (apoptosis). By keeping it closed, Imeglimin helps preserve pancreatic beta-cell mass, potentially slowing the progression of diabetes.

desertshores · January 24, 2026, 11:02pm

I ordered the same brand, and it’s on its way. I am hoping it will lower my fasting glucose levels.

Metformin worked fine for me until I developed an intolerance for it.
Glynase and empagliflozin do nothing for me, at least compared to metformin.

My fasting glucose is suboptimal, which is contrary to the rationale that we want all of our bloodwork to be optimal for longevity. I can lower my fasting glucose by fasting longer than usual and drinking lots of water before my blood test. My own in-home test tells a different story. My morning glucose reading after being up for two hours and fasting for 14 hours is always between 101 and 110. I would like it to be between 90 and 100.

Of course, my doctor is not concerned and will not prescribe further medications until my fasting glucose and A1C become significantly worse. Two doctors have told me that at my age, everything is okay. They are not longevity doctors.

qBx123Yk · January 24, 2026, 11:25pm

Tracking fasting insulin, and A1c will also be very useful.

cl-user · January 26, 2026, 12:47am

I just watched a video of an Indian talk about Imeglimin with lots of interesting slides such as that one:
(Note all the cool stuff about NAD+, CD38, etc.)

Slightly less cool is that adding it to GLP1-RA does not reduce HbA1C by much.
That said they have theories about why and on the other hand the combination with a SGLT2i is OK.
As usual the effect size is highly dependent on individual variability so I’m hopeful.

The full video is here:
Imeglimin Novel agent in T2D Armamentarium with Dual Benefits

Added Summary by @RapAdmin:

I. Executive Summary

This clinical presentation provides an in-depth mechanistic and clinical appraisal of imeglimin hydrochloride, a first-in-class tetrahydrotriazine antidiabetic agent (“glimin”) targeting mitochondrial bioenergetics to treat Type 2 Diabetes Mellitus (T2D). The presentation argues that imeglimin resolves the core pathophysiological triad of T2D—pancreatic beta-cell failure, skeletal muscle insulin resistance, and excess hepatic gluconeogenesis—via bioenergetic modulation rather than conventional receptor agonism or direct secretagogue stimulation.

Mechanistically, imeglimin modulates the mitochondrial electron transport chain (ETC) through partial, competitive inhibition of Complex I (NADH:ubiquinone oxidoreductase) and correction/restoration of deficient Complex III (coenzyme Q:cytochrome c oxidoreductase) activity. This dual modulation reduces forward and reverse electron leakage, suppresses reactive oxygen species (ROS) overproduction, prevents mitochondrial permeability transition pore (mPTP) opening, and aborts cytochrome c/caspase-mediated apoptotic signaling in beta cells. Concurrently, imeglimin upregulates nicotinamide phosphoribosyltransferase (NAMPT) salvage flux, elevating intracellular NAD+ pools to activate CD38/cyclic ADP-ribose (cADPR) signaling and trigger glucose-stimulated insulin secretion (GSIS) via Ryanodine receptor intracellular calcium mobilization.

Clinically, the presentation reviews Phase 3 registration data from the Japanese development program (TIMES 1, TIMES 2, and TIMES 3) alongside pooled meta-analyses. Imeglimin (1,000 mg BID) produces a placebo-subtracted HbA1c reduction of -0.79% to -0.90% as monotherapy and demonstrates sustained efficacy across dual combinations with DPP-4 inhibitors, SGLT2 inhibitors, biguanides, and basal insulin. However, add-on therapy with GLP-1 receptor agonists (GLP-1RAs) failed to demonstrate statistically significant HbA1c improvements, likely reflecting advanced beta-cell exhaustion or mechanistic pathway redundancy in refractory cohorts.

From a safety and pharmacokinetic perspective, imeglimin is excreted unchanged via the kidneys with minimal hepatic metabolism, low protein binding, and no CYP450 interactions or QTc prolongation. Unlike biguanides (phenformin, metformin), it does not induce lactic acidosis due to its distinct, non-exhaustive Complex I kinetic profile. Despite promising rodent models suggesting cardiorenal benefits in heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy, human cardiovascular and renal outcome trials (CVOTs) remain nonexistent, leaving extra-glycemic organ-protection claims translationally unproven.

II. Insight Bullets

Evolutionary Origin of Mitochondria: Human mitochondria originate from ancestral endosymbiotic alpha-proteobacteria that integrated into eukaryotic hosts while retaining distinct mitochondrial DNA (mtDNA) [01:00].
Inner Membrane Surface Area: Mitochondrial cristae maximize inner membrane surface area to host high-density electron transport chain complexes for oxidative phosphorylation [02:00].
Master Metabolic Regulator PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) acts as a primary transcriptional coactivator regulating mitochondrial biogenesis, gluconeogenesis, and fatty acid oxidation [02:30].
Tissue Distribution of PGC-1α: PGC-1α is predominantly expressed in high-metabolic-flux tissues including myocardium, skeletal muscle, hepatocytes, brown adipose tissue, and cerebral cortex [02:56].
Physiological Inducers of Biogenesis: Cold exposure, prolonged fasting, and vigorous aerobic exercise stimulate PGC-1α expression through physiological bioenergetic demand [03:11].
Pathological Downregulation in T2D: Skeletal muscle PGC-1α expression and downstream mitochondrial biogenesis are suppressed in states of chronic insulin resistance [03:25].
Bioenergetic Sensor Cross-Talk: The AMP/ATP and NAD+/NADH ratios tightly regulate AMP-activated protein kinase (AMPK) and Sirtuin 1 (SIRT1), directly modulating PGC-1α activation [03:45].
Nutrient Overload and Neuroplasticity: Sustained nutrient excess suppresses the AMPK/SIRT1/PGC-1α axis, impairing mitochondrial biogenesis and depressing neuronal plasticity [04:44].
Substrate Flux to Oxidative Phosphorylation: Cytoplasmic glycolysis yields pyruvate and acetyl-CoA, fueling the tricarboxylic acid (TCA) cycle to generate reducing equivalents (NADH and FADH2) for ETC complexes [05:08].
Electron Leakage and Superoxide Generation: Pathological mismatch between electron supply and terminal reduction causes electron leakage, reacting with molecular oxygen to generate superoxide anion radicals [05:59].
Apoptotic Triggering: Mitochondrial ROS generation triggers outer membrane permeabilization, releasing cytochrome c into the cytoplasm and activating caspase-dependent apoptosis [06:10].
Mitochondrial Dynamics in Beta Cells: T2D pathology disrupts balanced mitochondrial fission, fusion, and mitophagy, accelerating pancreatic beta-cell apoptosis [07:21].
Lipid Intermediate Accumulation: Impaired mitochondrial oxidative phosphorylation leads to intracellular accumulation of long-chain fatty acyl-CoAs, diacylglycerols (DAG), and ceramides, worsening insulin resistance [07:45].
Enzymatic Antioxidant Depletion: Chronic ETC hyperactivation exhausts endogenous superoxide dismutase (SOD) pools, increasing hydroxyl radical generation via Fenton-type reactions [08:21].
Impaired Mitophagic Clearance: Defective mitophagy prevents the selective degradation of damaged, depolarized mitochondria, leading to collateral destruction of healthy mitochondrial networks [09:49].
Dual Therapeutic Target Requirement: Effective T2D intervention requires simultaneous restoration of glucose-stimulated insulin secretion (GSIS) and mitigation of peripheral insulin resistance [10:36].
Imeglimin Molecular Classification: Imeglimin is the first chemical entity in the tetrahydrotriazine (“glimin”) class, distinct from biguanides due to its cyclic triazine structure [26:20].
Complex I Rebalancing: Imeglimin acts as a weak, competitive inhibitor of ETC Complex I, suppressing reverse electron transport (RET) and reducing ROS production [11:29].
Complex III Functional Restoration: Unlike biguanides, imeglimin selectively restores deficient Complex III activity, optimizing forward electron transport and maintaining transmembrane proton gradients [11:40].
Inhibition of mPTP Opening: Normalization of inner membrane potential prevents opening of the mitochondrial permeability transition pore (mPTP), preventing pro-apoptotic factor efflux [12:23].
Augmentation of Glucose-Stimulated Insulin Secretion: Increased glucose-dependent ATP synthesis enhances ATP-sensitive K+ channel closure, driving glucose-stimulated insulin release without inducing unprompted secretion [12:46].
Suppression of Hepatic Gluconeogenesis: Imeglimin lowers excessive hepatic glucose production and hepatic steatosis by normalizing hepatic mitochondrial bioenergetics [12:59].
Skeletal Muscle GLUT4 Translocation: Enhanced insulin-stimulated Akt phosphorylation in skeletal muscle promotes GLUT4 vesicle trafficking and peripheral glucose clearance [13:12].
NAD+ Salvage Pathway Flux: Imeglimin drives nicotinamide phosphoribosyltransferase (NAMPT) salvage activity, expanding the beta-cell intracellular NAD+ pool [13:55].
CD38/cADPR Calcium Signaling: Elevated NAD+ activates CD38 to synthesize cyclic ADP-ribose, inducing calcium release from intracellular stores via Ryanodine receptors (RyR) to amplify GSIS [14:29].
Preclinical Renal Protection Mechanisms: In rodent models, imeglimin reduced albuminuria and tubulointerstitial fibrosis by restoring renal Complex III subunits and suppressing oxidative stress [17:28].
Cardiomyocyte mPTP Modulation: Inhibition of myocardial mPTP opening preserves endothelial integrity and reduces ischemic cardiomyocyte apoptosis in preclinical systems [18:09].
Diastolic Function Preservation in Rodents: Diabetic rodent models showed improved left ventricular relaxation, reduced lipid peroxidation, and reduced myocardial ROS independent of systemic glycemic changes [19:40].
Unproven Cardiovascular Outcomes: The speaker acknowledges that clinical cardiovascular outcome data for imeglimin remain absent, contrasting with verified CVOT data for SGLT2 inhibitors [20:12].
TIMES 1 Monotherapy Glycemic Efficacy: In the pivotal Phase 3 TIMES 1 trial, imeglimin 1,000 mg BID achieved a placebo-adjusted HbA1c reduction of 0.90% at 24 weeks [20:45].
TIMES 1 Glycemic Target Attainment: In TIMES 1, 35.8% of imeglimin-treated patients reached HbA1c levels below 7.0%, compared to 7.5% in the placebo group [21:06].
TIMES 1 Safety Profile: Gastrointestinal adverse events were the most frequently reported side effects; hypoglycemia risk did not differ significantly from placebo [21:16].
TIMES 2 Long-Term Durability: The 52-week open-label TIMES 2 trial demonstrated long-term safety and durable glycemic control across monotherapy and oral add-on combinations [21:28].
TIMES 2 Combination with DPP-4 Inhibitors: The combination of imeglimin with DPP-4 inhibitors generated an additional HbA1c reduction of approximately 1.00% [22:28].
TIMES 2 Combination with Sulfonylureas: Add-on therapy with sulfonylureas produced a modest 0.56% HbA1c reduction but increased hypoglycemia incidence (up to 16.5%) [22:09].
TIMES 3 Insulin Add-On Efficacy: In TIMES 3, imeglimin added to basal insulin therapy produced a statistically significant 0.60% HbA1c reduction at 16 weeks, sustained through 52 weeks [23:27].
Pooled Meta-Analyses Findings: Systematic reviews show imeglimin 1,000 mg BID monotherapy lowers HbA1c by an average of 0.79% to 0.90%, equivalent to standard oral antihyperglycemic drugs [24:21].
Failure of Synergy with GLP-1RAs: In TIMES 2, imeglimin add-on to GLP-1 receptor agonists failed to demonstrate significant glycemic improvement, likely due to advanced disease duration (~11 years) or overlapping beta-cell pathway saturation [25:17].
Absence of Lactic Acidosis: Clinical trials reported zero cases of treatment-induced lactic acidosis, attributable to imeglimin’s mild Complex I kinetics and selective Complex III enhancement [25:58].
Chemical Pharmacophore Differences: Unlike metformin’s linear biguanide chain, imeglimin incorporates a central tetrahydrotriazine ring with a dimethylamino substituent, modifying tissue distribution and transporter binding [26:27].
Elimination Kinetics: Imeglimin displays a 13-hour elimination half-life and is excreted predominantly unchanged via urine without significant hepatic phase I/II metabolism [26:56].
Renal Dose-Adjustment Thresholds: Standard dosing (1,000 mg BID) applies for eGFR >45 mL/min/1.73m2; dosing must be halved to 500 mg BID for eGFR 15–45 mL/min/1.73m2 [27:07].
Hepatic Impairment Parameters: No dose adjustments are required for Child-Pugh Class A or B hepatic impairment, though clinical data in Child-Pugh Class C (severe) are absent [27:26].
Cardiac Electrophysiology: Thorough QT clinical studies revealed no QTc interval prolongation or arrhythmogenic liability across tested dose ranges [27:57].
Inter-Ethnic Pharmacokinetic Equivalence: Comparative phase 1 pharmacokinetic analyses demonstrated no meaningful differences between Japanese and Caucasian pharmacokinetic profiles [28:07].
Buccal Electrospun Nanofiber Delivery: Exploratory formulation research incorporates imeglimin into electrospun polymeric nanofibers for transmucosal buccal delivery to bypass gastrointestinal intolerance, though human clinical trial data remain absent [29:18].

III. Adversarial Claims & Evidence Table

Claim from Video	Speaker’s Evidence	Scientific Reality (Current Data)	Evidence Grade	Verdict
Imeglimin monotherapy lowers HbA1c by ~0.90% at 24 weeks	TIMES 1 Phase 3 Japanese trial data [20:45].	Confirmed in double-blind RCT (Dubourg et al., 2021) showing placebo-adjusted -0.87% (-9.5 mmol/mol) HbA1c reduction. Confirmed in systematic meta-analysis (Dutta et al., 2023).	Level A	Strong Support
Imeglimin provides safe, effective add-on to insulin with ~0.60% HbA1c reduction	TIMES 3 trial at 16 and 52 weeks [23:07].	Verified in double-blind RCT (Reaven et al., 2022), showing adjusted mean HbA1c difference of -0.60% (95% CI: -0.80 to -0.40) with no severe hypoglycemia.	Level B	Strong Support
Imeglimin exhibits robust synergistic HbA1c lowering with DPP-4 inhibitors (~1.0% drop)	TIMES 2 open-label sub-analysis [22:28].	Verified in the TIMES 2 52-week open-label trial (Ishii et al., 2022). DPP-4i combination produced superior HbA1c lowering (-0.92% to -1.00%) compared to other combinations.	Level B	Strong Support
Imeglimin exerts dual action: increases GSIS and decreases hepatic gluconeogenesis	Cellular bioenergetic models and animal clamped assays [10:59].	Preclinical and clinical clamp studies confirm enhanced beta-cell glucose responsiveness and reduced hepatic glucose output (Hallakou-Bozec et al., 2021). Human clamp data show improved first-phase insulin secretion.	Level B	Strong Support
Complex I/III rebalancing suppresses ROS and prevents mPTP opening	Bioenergetic models showing competitive Complex I inhibition and Complex III restoration [11:29].	In vitro isolated mitochondrial studies demonstrate partial Complex I inhibition, Complex III subunit normalization, and suppressed mPTP opening (Vial et al., 2021). Direct in vivo human ETC kinetics remain unmeasured.	Level D	Plausible (Translational Gap)
Imeglimin activates NAMPT/NAD+/CD38/cADPR pathway to drive calcium-mediated GSIS	Rodent islet bioenergetics and RyR receptor activation diagrams [13:55].	Rodent and isolated islet studies confirm that imeglimin upregulates NAMPT-mediated NAD+ synthesis, driving CD38/cADPR/RyR calcium flux (Hallakou-Bozec et al., 2021). Human islet verification is limited.	Level D	Plausible (Translational Gap)
Imeglimin confers direct renoprotection (decreases albuminuria and fibrosis)	Mouse diabetic nephropathy models [17:28].	Documented in rodent models (Kaku et al., 2023). However, dedicated human renal outcome trials (DKD endpoints) are entirely absent.	Level D	Speculative (Translational Gap)
Imeglimin reverses diabetic cardiomyopathy and HFpEF	HFpEF mouse models and diabetic rat left ventricular studies [19:20].	Rodent studies demonstrate endothelial and left ventricular improvements (Kaku et al., 2023). Small retrospective human observational pilot (Yuki et al., 2024) showed safety in heart failure, but large-scale human CVOTs are non-existent.	Level C	Speculative (Translational Gap)
Add-on therapy with GLP-1 receptor agonists provides negligible glycemic benefit	TIMES 2 sub-group data [25:17].	TIMES 2 (Ishii et al., 2022) confirmed an insignificant HbA1c drop (-0.12%) when adding imeglimin to GLP-1RAs. Hypothesized to stem from long-standing beta-cell depletion or overlapping downstream pathways.	Level B	Strong Support
Imeglimin carries near-zero risk of lactic acidosis compared to metformin	Pharmacological safety profiles and absence of clinical cases [25:58].	Zero lactic acidosis cases observed in clinical trial programs or post-marketing surveillance (Fallahi et al., 2025). Explained by weaker, competitive Complex I inhibition that preserves basal oxidative phosphorylation.	Level A	Strong Support
Electrospun buccal nanofibers eliminate GI adverse events in humans	Electron microscopy diagram of nanofiber formulations [28:55].	Exclusively in vitro formulation chemistry. No Phase 1 human pharmacokinetic or tolerability trials published.	Level D	Unsupported (Translational Gap)